Published · Aurelis Peptides
GLOW lists GHK, BPC and TB. The KLOW source line lists KPV, GHK and BPC. Both written lines show GHK 50 mg and BPC 10 mg. GLOW names TB 10 mg; the KLOW line names KPV 10 mg. That is the useful starting point for a KLOW vs GLOW comparison.
There is one unresolved detail: the KLOW source sheet shows an 80 mg total, but its written components add to 70 mg. Aurelis therefore keeps KLOW as specification on request. It should not be presented as a confirmed 80 mg formulation.
KLOW vs GLOW at a glance
| Field | GLOW | KLOW source line |
|---|---|---|
| GHK | 50 mg | 50 mg |
| BPC | 10 mg | 10 mg |
| Third named component | TB 10 mg | KPV 10 mg |
| Written component sum | 70 mg | 70 mg |
| Source-sheet total | 70 mg | 80 mg; does not reconcile |
| Current catalogue entry | GLOW 70 mg | Specification on request |
The table follows the existing Aurelis blend specification guide. It compares the written records; it does not fill the missing detail in the KLOW formulation.
Is KLOW simply GLOW with KPV added?
That description does not match the written line we have. Adding KPV 10 mg to the listed GLOW components would produce a four-component, 80 mg combination. The KLOW source line names only KPV, GHK and BPC. It does not name TB.
We cannot settle the discrepancy by adding a fourth ingredient or changing a listed amount. Nor should the 80 mg label be silently replaced with 70 mg as a confirmed specification. The missing answer is a corrected, complete component sheet for the material being offered.
What do GHK, BPC and TB identify?
These are the abbreviations used on the source sheet. Keep them intact while asking for the complete ingredient names. The separate catalogue entries for GHK-Cu, BPC-157 and TB-500 provide background on those names; they do not resolve a blend abbreviation.
In particular, GHK should not automatically be rewritten as GHK-Cu. Our GHK vs GHK-Cu guide explains that naming distinction. KPV also has its own catalogue profile, separate from the unresolved KLOW formulation.
What does the total tell you?
A total adds the stated component amounts. It does not show which blend has a greater effect or is better suited to a particular purpose. Here, even the written 70 mg sums represent different named combinations.
Keep the complete component line beside the total when comparing an enquiry reply. Neither a 70 mg label nor an 80 mg label specifies a liquid fill volume, concentration or amount delivered by a device. The content vs concentration guide covers those units separately.
Choose the blend and presentation separately
Both vials and pen-style kit presentations remain part of Aurelis enquiries. A kit photograph does not confirm the formulation inside it. First identify the blend and its accepted component sheet; then ask which presentation is available for that specification.
For a focused reply, send the blend name, preferred vial or kit format, requested unit count and destination in Australia, Canada or the USA. For KLOW, specifically ask for the reconciled total and every component amount. For GLOW, retain the listed three-component line in your enquiry.
Ask about KLOW or GLOW, or email sales@aurelispeptides.com. Request the matching product and batch records with the reply so the offered specification can be checked against the catalogue.